Top 10 Mid-size Pharma Companies (mainly specialty) in the US in 2021 by Revenues

Exelixis Inc, Neurocrine Biosciences Inc, Ionis Pharmaceuticals Inc, Pacira BioSciences Inc, and Acadia Pharmaceuticals Inc are the top 5 Mid-size Pharma Companies (mainly specialty) in the US in 2021 by revenue. Cumulatively, the top 10 Mid-size Pharma Companies (mainly specialty) generated revenue of $6,407 million, the highest revenue was generated by Exelixis Inc ($1,435 million), followed by Neurocrine Biosciences Inc ($1,134 million) and Ionis Pharmaceuticals Inc ($810 million), while Harmony Biosciences Holdings Inc ($305 million) stood the lowest. Exelixis Inc is the leading Mid-size Pharma Companies in the US in 2021 by Revenue (FY 2021). It is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company’s marketed products include Cometriq (cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). Neurocrine Biosciences Inc is one of the top Mid-size Pharma Companies in the US in 2021 by Revenue (FY 2021). It discovers, develops, and sells pharmaceutical products for the treatment of neurologic, neuropsychiatric, and neuroendocrine-related diseases and disorders. Its lead product, Ingrezza (valbenazine) capsule, is a US FDA-approved selective vesicular monoamine transporter 2 inhibitor for the treatment of adults with tardive dyskinesia (TD).